A new face in the treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia

The prognosis for patients with relapsed/refractory or measurable (minimal) residual disease‐positive Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukaemia (ALL) is poor. Currently, ponatinib is the only approved tyrosine kinase inhibitor (TKI) that is effective for Ph‐positive ALL with the T315I mutation. Although the report by Liu et al. is a retrospective observational study, it offers prospects for the efficacy of chemotherapy combined with the novel third‐generation TKI, olverembatinib, in these conditions, which may be validated in future prospective clinical trials. Commentary on: Liu et al. Efficacy and safety of olverembatinib in adult BCR::ABL1‐positive ALL with T315I mutation or relapsed/refractory disease. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19804 .